Redhawk Wealth Advisors Inc. Reduces Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Redhawk Wealth Advisors Inc. cut its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 14.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 32,592 shares of the biopharmaceutical company's stock after selling 5,443 shares during the quarter. Redhawk Wealth Advisors Inc.'s holdings in Halozyme Therapeutics were worth $2,080,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Venturi Wealth Management LLC acquired a new position in shares of Halozyme Therapeutics during the 4th quarter worth approximately $69,000. Shaker Investments LLC OH increased its position in shares of Halozyme Therapeutics by 12.3% during the fourth quarter. Shaker Investments LLC OH now owns 75,326 shares of the biopharmaceutical company's stock worth $3,601,000 after purchasing an additional 8,249 shares in the last quarter. D. E. Shaw & Co. Inc. increased its position in shares of Halozyme Therapeutics by 171.2% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock worth $39,750,000 after purchasing an additional 524,802 shares in the last quarter. Davidson Capital Management Inc. increased its position in shares of Halozyme Therapeutics by 111.2% during the fourth quarter. Davidson Capital Management Inc. now owns 56,639 shares of the biopharmaceutical company's stock worth $2,708,000 after purchasing an additional 29,826 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Halozyme Therapeutics by 0.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,783,177 shares of the biopharmaceutical company's stock worth $85,254,000 after purchasing an additional 9,780 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Trading Down 1.0%

Shares of Halozyme Therapeutics stock traded down $0.56 during trading hours on Friday, hitting $53.98. The company's stock had a trading volume of 1,218,546 shares, compared to its average volume of 1,634,157. Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $70.51. The firm has a fifty day moving average of $57.34 and a 200-day moving average of $56.13. The stock has a market cap of $6.65 billion, a price-to-earnings ratio of 15.74, a P/E/G ratio of 0.42 and a beta of 1.19. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.13. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The firm had revenue of $264.86 million for the quarter, compared to analyst estimates of $231.21 million. During the same quarter in the prior year, the company earned $0.79 EPS. Halozyme Therapeutics's revenue was up 35.2% on a year-over-year basis. Research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on HALO. JPMorgan Chase & Co. boosted their price target on Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a research report on Monday, April 21st. HC Wainwright reiterated a "buy" rating and set a $72.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, May 29th. Morgan Stanley cut Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and dropped their target price for the company from $73.00 to $62.00 in a report on Wednesday, May 14th. Wells Fargo & Company upped their target price on Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a report on Wednesday, May 7th. Finally, Leerink Partnrs cut Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, May 13th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, Halozyme Therapeutics presently has an average rating of "Hold" and a consensus price target of $61.90.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 503 shares of the stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total value of $32,217.15. Following the sale, the director now owns 33,108 shares of the company's stock, valued at $2,120,567.40. This trade represents a 1.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.40% of the stock is owned by corporate insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.